Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

ASC4FIRST Trial Supports Asciminib With Secondary End Points in CML ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's ...

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's ...

Panelists discuss how venous thromboembolism risk assessment and prophylaxis decisions in patients with non–small cell lung cancer require careful consideration of individual risk factors, patient ...

Panelists discuss how adverse event profiles, management strategies, and patient education approaches differ among EGFR-targeted therapies for non–small cell lung cancer, including oral tyrosine ...

The study's findings have implications for early detection and prevention of breast cancer, suggesting that chromosomal ...

Panelists discuss how the availability of subcutaneous amivantamab influences nursing approaches to patient care and education, with Squires sharing strategies for ensuring patients understand the new ...

Medical experts discuss strategies for educating patients on managing side effects of osimertinib and other EGFR inhibitors, with guidance on recognizing symptoms that warrant contacting their care ...

Profiling a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope ...

Panelists discuss how amivantamab’s dual targeting of EGFR and MET may address resistance mechanisms and unmet needs in EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Dr Scott ...